CordenPharma This allows for continuous solution-phase synthesis with simple aqueous workups. The organic phase is then carried over for the next coupling and cleavage cycle. Compared to SPPS, TAPS improves efficiency, sustainability, and scale. It eliminates resin handling, drastically cuts solvent use, and simplifies purification. Unlike LPPS, TAPS retains precise stepwise control, allowing full compatibility with SPPS reagents and know-how. TAPS provides a greener, more economical alternative that integrates into existing smallmolecule assets, enabling broad application without investment in peptide-specific hardware. This innovation opens the door for automation, modular synthesis (fragment approaches), and green manufacturing practices. It directly supports pharmaceutical trends toward flexible, scalable production of complex, high-value APIs under increasing regulatory scrutiny. TAPS is not just a lab-scale improvement - it’s an industrial innovation ready for GMP rollout, with clear benefits for pharma innovators. Figure 1. (CordenPharma Photo) Preparation of peptide synthesis using TAPS technology at CordenPharma Liestal (CH). CordenPharma CEO & President Dr. Michael Quirmbach stands out among the finalists thanks to his visionary leadership, not only to drive business success, but also to support pharmaceutical innovators in advancing the care of their global patient communities with impactful outsourcing innovations. His ambitious goal is to position CordenPharma among the top five CDMOs globally, recognized for its unwavering commitment to customer centricity and scientific excellence. CEO of the Year Dr. MICHAEL QUIRMBACH CEO & President CordenPharma Group 15 CPHI FRANKFURT 2025 PREVIEW
RkJQdWJsaXNoZXIy MjY2OTA4MA==